Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Ching-Jung Hsieh & Feng-Chih Shen. (2014) The durability of sitagliptin in elderly patients with type 2 diabetes. Clinical Interventions in Aging 9, pages 1905-1911.
Read now
Read now
Thomas Forst & Peter Bramlage. (2014)
Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. Expert Opinion on Pharmacotherapy 15:9, pages 1299-1313.
Read now
Read now
Tse-Ying Chen & Ching-Jung Hsieh. (2014) Real-World Effectiveness of Sitagliptin as Add-On Therapy in Patients With Type 2 Diabetes Mellitus. Postgraduate Medicine 126:3, pages 205-215.
Read now
Read now
Baptist Gallwitz. (2011) Sitagliptin and metformin combination therapy for the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 6:4, pages 543-556.
Read now
Read now
Niki Katsiki, Dimitri P Mikhailidis, Anna Gotzamani-Psarrakou, John G Yovos & Dimitrios Karamitsos. (2011) Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opinion on Therapeutic Targets 15:4, pages 401-420.
Read now
Read now
Niki Katsiki, Nikolaos Papanas & Dimitri P Mikhailidis. (2010) Dapagliflozin: more than just another oral glucose-lowering agent?. Expert Opinion on Investigational Drugs 19:12, pages 1581-1589.
Read now
Read now
André J Scheen. (2010) Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opinion on Drug Metabolism & Toxicology 6:10, pages 1265-1276.
Read now
Read now
Shannon A Miller, Erin L St Onge & J Roger Accardi. (2009) Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity 2, pages 23-30.
Read now
Read now
N Papanas, E Maltezos & DP Mikhailidis. (2009) Metformin: diamonds are forever. Expert Opinion on Pharmacotherapy 10:15, pages 2395-2397.
Read now
Read now
Articles from other publishers (11)
Jung-Fu Chen, Chih-Min Chang, Ming-Chun Kuo, Shih-Chen Tung, Cheng-Feng Tsao & Chia-Jen Tsai. (2016) Impact of baseline body mass index status on glucose lowering and weight change during sitagliptin treatment for type 2 diabetics. Diabetes Research and Clinical Practice 120, pages 8-14.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
419
458
.
Sneha R. Sagar, Jessica K. Agarwal, Dhaivat H. Pandya, Ranjeet Prasad Dash, Manish Nivsarkar & Kamala K. Vasu. (2015) Design, synthesis and biological evaluation of novel pyrazolo-pyrimidinones as DPP-IV inhibitors in diabetes. Bioorganic & Medicinal Chemistry Letters 25:20, pages 4428-4433.
Crossref
Crossref
Di-Wei Mo, Shuai Dong, Haiyan Sun, Jia-Sheng Chen, Jian-Xin Pang, Bao-Min Xi & Wen-Hua Chen. (2015) Synthesis and potent inhibitory activities of carboxybenzyl-substituted 8-(3-(R)-aminopiperidin-1-yl)-7-(2-chloro/cyanobenzyl)-3-methyl-3,7-dihydro-purine-2,6-diones as dipeptidyl peptidase IV (DPP-IV) inhibitors. Bioorganic & Medicinal Chemistry Letters 25:9, pages 1872-1875.
Crossref
Crossref
Noriyasu Kato, Mitsuru Oka, Takayo Murase, Masahiro Yoshida, Masao Sakairi, Satoko Yamashita, Yoshika Yasuda, Aya Yoshikawa, Yuuji Hayashi, Mitsuhiro Makino, Motohiro Takeda, Yakufu Mirensha & Takuji Kakigami. (2011) Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorganic & Medicinal Chemistry 19:23, pages 7221-7227.
Crossref
Crossref
P. Anagnostis, V. G. Athyros, F. Adamidou, A. Panagiotou, M. Kita, A. Karagiannis & D. P. Mikhailidis. (2011) Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes, Obesity and Metabolism 13:4, pages 302-312.
Crossref
Crossref
Chidambarann SudhakaranUtkal KishoreRanjit Mohan AnjanaRanjit UnnikrishnanViswanathan Mohan. (2011) Effectiveness of Sitagliptin in Asian Indian Patients with Type 2 Diabetes—An Indian Tertiary Diabetes Care Center Experience. Diabetes Technology & Therapeutics 13:1, pages 27-32.
Crossref
Crossref
Y. Iwamoto, N. Tajima, T. Kadowaki, K. Nonaka, T. Taniguchi, M. Nishii, J. C. Arjona Ferreira & J. M. Amatruda. (2010) Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes, Obesity and Metabolism 12:7, pages 613-622.
Crossref
Crossref
Michelle L. Griffith, Lisa M. Younk & Stephen N. Davis. (2010) Visceral Adiposity, Insulin Resistance, and Type 2 Diabetes. American Journal of Lifestyle Medicine 4:3, pages 230-243.
Crossref
Crossref
Feng Xu, Edward Corley, Michael Zacuto, David A. Conlon, Brenda Pipik, Guy Humphrey, Jerry Murry & David Tschaen. (2010) Asymmetric Synthesis of a Potent, Aminopiperidine-Fused Imidazopyridine Dipeptidyl Peptidase IV Inhibitor. The Journal of Organic Chemistry 75:5, pages 1343-1353.
Crossref
Crossref
. (2009) Current World Literature. Current Opinion in Lipidology 20:6, pages 512-519.
Crossref
Crossref